Harmony Biosciences Holdings, Inc. (HRMY)
$37.03-3.14%Close
SELLBEAR · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.1B
- Beta
- 1.01
- P/E (TTM)
- 11.83
- Short % float
- 10.98%
- Days to cover
- 5.0
- SI change
- +19.5%
- 1W
- -5.92%
- 1M
- -10.86%
- vs SPY 1W
- -5.78%
- vs SPY 1M
- -13.36%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 70
- VALUE
- 49
- GROWTH
- 75
- GARP
- 71
- TYPE
- Value / Recovery (blended)
Composite of Value · Growth · GARP
ROIC12.0%
REV YoY-
ROE20.1%
EPS YoY-
ROA13.2%
GROSS75
OP24
NET19
[VALUATION]
P/E TTM11.83
P/E FWD9.70
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.14
P/FCF-
EV/EBITDA6.32
EV/EBIT-
PEG1.16
FCF YIELD-
RISK
INT COV-
D/E15.41
ALTMAN Z-
CURR RATIO3.48
ND/EBITDA-
BETA1.01
Company news
FAQ
- What is LOPJLB’s current signal on HRMY?
- LOPJLB’s latest quantitative signal on Harmony Biosciences Holdings, Inc. (HRMY) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is HRMY in?
- Harmony Biosciences Holdings, Inc. (HRMY) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Harmony Biosciences Holdings, Inc. (HRMY) do?
- Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 201…